Anti-HCMV compositions and methods
Inventors
Remiszewski, Stacy • Koyuncu, Emre • Sun, Qun • Chiang, Lillian
Assignees
Publication Number
US-10556894-B2
Publication Date
2020-02-11
Expiration Date
2035-11-09
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Novel compounds useful for treating and/or preventing HCMV infections are provided.
Core Innovation
The invention provides novel compounds having the structure of Formula I and various related formulas, as well as pharmaceutically acceptable salts thereof, which are useful for preventing, treating, or ameliorating human cytomegalovirus (HCMV) infection. These compounds are defined by specific structural features detailed in the patent, including various possible substitutions and functional groups.
The problem addressed by the invention arises from the high prevalence and severity of HCMV infections, particularly in immunosuppressed individuals such as organ transplant recipients. Existing HCMV antivirals, such as ganciclovir, are limited by nephrotoxic side effects and increasing rates of drug resistance, which negatively impact graft and patient survival. HCMV-mediated immune modulation can also reactivate latent viruses in adults, further complicating treatment.
The invention discloses methods for treating or preventing HCMV infection by administering a therapeutically effective amount of the disclosed compounds. The compounds may inhibit HCMV production in infected cells and can be administered alone or in conjunction with other antiviral agents. Various synthetic routes and pharmaceutical formulations are described, demonstrating how these compounds can be practically prepared and delivered.
Claims Coverage
The patent includes a series of independent claims that define five inventive features relating to compositions and one relating to methods for treating HCMV infection.
Composition comprising a compound of Formula II or a pharmaceutically acceptable salt thereof
A composition containing a compound of Formula II, as structurally defined in the patent, or a pharmaceutically acceptable salt thereof.
Composition comprising a compound of Formula III or a pharmaceutically acceptable salt thereof
A composition containing a compound of Formula III, as structurally defined in the patent, or a pharmaceutically acceptable salt thereof.
Composition comprising a compound of Formula IV or a pharmaceutically acceptable salt thereof
A composition containing a compound of Formula IV, as structurally defined in the patent, or a pharmaceutically acceptable salt thereof.
Composition comprising a compound of Formula VI or a pharmaceutically acceptable salt thereof
A composition containing a compound of Formula VI, as structurally defined in the patent, or a pharmaceutically acceptable salt thereof.
Composition comprising a compound of Formula VII or a pharmaceutically acceptable salt thereof
A composition containing a compound of Formula VII, as structurally defined in the patent, or a pharmaceutically acceptable salt thereof.
Method for treating HCMV infection by administering a compound of Formula I
A method for treating a HCMV infection in a subject that consists of administering a therapeutically effective amount of a compound of Formula I as described in the patent, or a pharmaceutically acceptable salt thereof.
In summary, the patent claims cover pharmaceutical compositions comprising several structurally-defined compound classes (Formulas II, III, IV, VI, and VII) or salts, and includes a method claim for treating HCMV infection by administering a compound of Formula I or its salts.
Stated Advantages
The compounds are useful for treating and/or preventing HCMV infections, including in cases where existing antivirals are limited by nephrotoxicity and drug resistance.
Documented Applications
Treatment, prevention, or amelioration of human cytomegalovirus (HCMV) infections in humans or other animals, particularly mammals.
Inhibition of HCMV production in infected cells.
Interested in licensing this patent?